Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
2023年11月7日 - 3:00PM
Valneva to Present and Hold Investor Meetings at the Jefferies
London Healthcare Conference
Saint-Herblain (France), November 7, 2023 – Valneva SE (Nasdaq:
VALN; Euronext Paris: VLA), a specialty vaccine company, today
announced that its senior management will present and participate
in 1-on-1 meetings with institutional investors at the Jefferies
London Healthcare Conference, to take place November 14-16, 2023 in
London, UK.
Chief Executive Officer Thomas Lingelbach and
Chief Financial Officer Peter Bühler will host a fireside chat at
2:30pm GMT on November 14 to discuss Valneva’s commercial business
and pipeline of infectious disease vaccines. This includes VLA1553,
which has a U.S. Food and Drug Administration (FDA) PDUFA
action date at the end of November 2023 and may, if approved,
become the first licensed chikungunya vaccine; and VLA15, the
Company’s Lyme vaccine candidate, currently in Phase 3 clinical
development and partnered with Pfizer Inc. (NYSE: PFE).
The live webcast of the fireside chat can be
accessed here. A replay of the webcast will be available following
the live events in the “Investor” section of the Valneva website at
www.valneva.com. To request a meeting at the event, please contact
your representative at Jefferies.
About Valneva SE
We are a specialty vaccine company that develops, manufactures,
and commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple
vaccine modalities, focused on providing either first-, best- or
only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines
from early R&D to approvals, and currently market two
proprietary travel vaccines as well as certain third-party vaccines
leveraging our established commercial infrastructure.
Revenues from our growing commercial business help fuel the
continued advancement of our vaccine pipeline. This includes the
only Lyme disease vaccine candidate in advanced clinical
development, which is partnered with Pfizer, potentially the
world’s first vaccine against the chikungunya virus, as well as
vaccine candidates against the Zika virus and other global public
health threats.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP, Global Communications and European Investor
RelationsM +33 (0)6 4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor Relations M +001
917 815 4520joshua.drumm@valneva.com |
|
|
Forward-Looking StatementsThis
press release contains certain forward-looking statements relating
to the business of Valneva, including with respect to regulatory
approval of VLA1553 and timing and plans for clinical programs and
clinical trials. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be indicative of future results. In
some cases, you can identify forward-looking statements by words
such as "could," "should," "may," "expects," "anticipates,"
"believes," "intends," "estimates," "aims," "targets," or similar
words. These forward-looking statements are based on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, the ability to obtain or
maintain patent or other proprietary intellectual property
protection and the impact of the COVID-19 pandemic. In light of
these risks and uncertainties, there can be no assurance that the
forward-looking statements made in this press release will in fact
be realized. Valneva is providing the information in this press
release as of the date hereof and disclaims any intention or
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
- 2023_11_07_VLA Jefferies_Curtain_Raiser_PR_EN_Final
Valneva (TG:AYJ)
過去 株価チャート
から 8 2024 まで 9 2024
Valneva (TG:AYJ)
過去 株価チャート
から 9 2023 まで 9 2024